Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO

Executive Summary

Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.

Advertisement

Related Content

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing
Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds
Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Boehringer Breathes Easy Over Spiriva Patent Expiry In US
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel